ReviewFrontiers in endocrinology2025
Can vitamin D supplementation be dangerous? 25-Hydroxyvitamin D and 1,25-hydroxyvitamin D concentration in healthy population and primary hyperparathyroidism: a single-center experience and literature review.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin D in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperparathyroidism (PHPT) is an excessive secretion of PTH caused by a defect in parathyroid cells, insensitive to the suppressive effects of hypercalcemia. The effect of 25-hydroxyvitamin D3 (25-OH-D) and skeletal and extra-skeletal conditions is well known, but the impact of 25-OH-D and 1,25-OH-D in the pathogenesis of primary hyperparathyroidism (PHPT) is still poorly researched. The study group (SG) consists of 85 patients with diagnosed PHPT. The control group (CG) consists of 51 patients without calcium-phosphate imbalance. The SG was divided into two subgroups: SG1 (patients with PHPT qualified for conservative management) and SG2 (patients who are qualified for surgical treatment). Serum PTH, calcium and phosphates concentration were assessed as well as the concentration of 25-OH-D and 1,25-OH-D. The ratio of 1,25-OH-D to 25-OH-D was introduced: vitamin D activation ratio (VD-AR). The median concentration of 25-OH-D3: 30,00 ng/mL in CG, 32,75 ng/ml in SG1 and 27,6 ng/mL in SG2. The highest 1,25-OH-D3 median concentration was found among patients in SG2 (91,1 pg/mL) lower in SG1 (64,05 pg/mL) and the lowest in CG (46,20 pg/mL). VD-AR was highest in SG2 as well, with median 3,32. Results given prove the statistically significant differences between the medians of 1,25-OH-D and VD-AR between pairs of all groups (e.g. SG1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.